These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21893353)

  • 1. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
    Switzer CH; Glynn SA; Ridnour LA; Cheng RY; Vitek MP; Ambs S; Wink DA
    Trends Pharmacol Sci; 2011 Nov; 32(11):644-51. PubMed ID: 21893353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.
    Switzer CH; Cheng RY; Ridnour LA; Glynn SA; Ambs S; Wink DA
    Breast Cancer Res; 2012 Sep; 14(5):R125. PubMed ID: 22971289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.
    Switzer CH; Glynn SA; Cheng RY; Ridnour LA; Green JE; Ambs S; Wink DA
    Mol Cancer Res; 2012 Sep; 10(9):1203-15. PubMed ID: 22878588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
    Basudhar D; Glynn SA; Greer M; Somasundaram V; No JH; Scheiblin DA; Garrido P; Heinz WF; Ryan AE; Weiss JM; Cheng RYS; Ridnour LA; Lockett SJ; McVicar DW; Ambs S; Wink DA
    Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13030-13035. PubMed ID: 29087320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications.
    Cristóbal I; Torrejón B; Martínez-Useros J; Madoz-Gurpide J; Rojo F; García-Foncillas J
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):435-438. PubMed ID: 28916342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer.
    Ambs S; Glynn SA
    Cell Cycle; 2011 Feb; 10(4):619-24. PubMed ID: 21293193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the predictive response of a simple and sensitive blood-based biomarker between estrogen-negative solid tumors.
    Mohan S; Patel S; Barlow D; Rojas AC
    Adv Med Sci; 2020 Sep; 65(2):424-428. PubMed ID: 32919119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.
    Glynn SA; Boersma BJ; Dorsey TH; Yi M; Yfantis HG; Ridnour LA; Martin DN; Switzer CH; Hudson RS; Wink DA; Lee DH; Stephens RM; Ambs S
    J Clin Invest; 2010 Nov; 120(11):3843-54. PubMed ID: 20978357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.
    López-Sánchez LM; Mena R; Guil-Luna S; Mantrana A; Peñarando J; Toledano-Fonseca M; Conde F; De la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
    Lab Invest; 2021 Mar; 101(3):292-303. PubMed ID: 33262438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein phosphatase 2A: a target for anticancer therapy.
    Perrotti D; Neviani P
    Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional importance of PP2A regulatory subunit loss in breast cancer.
    Watt LF; Panicker N; Mannan A; Copeland B; Kahl RGS; Dun MD; Young B; Roselli S; Verrills NM
    Breast Cancer Res Treat; 2017 Nov; 166(1):117-131. PubMed ID: 28744751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
    Naderi A; Meyer M
    Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altersolanol B, a fungal tetrahydroanthraquinone, inhibits the proliferation of estrogen receptor-expressing (ER+) human breast adenocarcinoma by modulating PI3K/AKT, p38/ERK MAPK and associated signaling pathways.
    Siraj MA; Jacobs AT; Tan GT
    Chem Biol Interact; 2022 May; 359():109916. PubMed ID: 35346647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status.
    Gopalakrishna R; Gundimeda U; Fontana JA; Clarke R
    Cancer Lett; 1999 Mar; 136(2):143-51. PubMed ID: 10355743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
    Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
    Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.